Latest News

Common multiple sclerosis drugs taken together do not reduce relapse risk

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Report recommends insurers use prescription monitoring data to reduce opioid abuse, deaths

  • Almost one-third of Canadian adults have experienced child abuse

  • Coming up with explanations helps children develop cause-and-effect thinking skills

  • Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches

  • Stroke treatment, outcomes improve with new initiative

  • Newly-approved brain stimulator offers hope for individuals with uncontrolled epilepsy

  • Cyber buddy is better than 'no buddy'

  • Innovation improves drowsy driver detection

  • Multiple sclerosis: Review of current treatments for physicians

  • Researchers compare hip width and sexual behavior

  •